New drug duo aims to outsmart resistant lung cancer
NCT ID NCT07285148
Summary
This study is testing a new two-drug combination for people with a specific type of advanced lung cancer that has spread. The goal is to find a safe dose and see if the combination can help shrink tumors or stop them from growing. The trial is for adults whose cancer has a genetic change called an EGFR mutation and has developed resistance to standard targeted therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center David H, Koch Center lor Cancer Care
New York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.